Compare NPCE & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPCE | VALN |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 623.0M | 536.9M |
| IPO Year | 2021 | 2021 |
| Metric | NPCE | VALN |
|---|---|---|
| Price | $16.31 | $5.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $18.33 | $15.50 |
| AVG Volume (30 Days) | ★ 199.4K | 69.2K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,986,000.00 | N/A |
| Revenue This Year | $0.90 | N/A |
| Revenue Next Year | $24.46 | $93.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.13 | N/A |
| 52 Week Low | $7.56 | $5.06 |
| 52 Week High | $19.60 | $12.25 |
| Indicator | NPCE | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 48.72 |
| Support Level | $15.17 | $5.81 |
| Resistance Level | $17.04 | $6.53 |
| Average True Range (ATR) | 1.17 | 0.25 |
| MACD | -0.24 | 0.12 |
| Stochastic Oscillator | 42.86 | 53.46 |
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.